logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Statistical bulletin 2007 search results

Statistics found here the keyword is cannabis

Category Title
SZR SZR-1. Number of cannabis resin seizures, 1995 to 2005
SZR SZR-2. Quantities (kg) of cannabis resin seized, 1995 to 2005
SZR SZR-3. Number of herbal cannabis seizures, 1995 to 2005
SZR SZR-4. Quantities (kg) of herbal cannabis seized, 1995 to 2005
SZR SZR-5. Number of seizures of cannabis plants, 1995 to 2005
SZR SZR-6. Quantities (number of plants) of cannabis plants seized, 1995 to 2005
PPP PPP-1. Price of cannabis products at retail level, 2005 Part (i) Minimum, maximum, mean and modal (typical) price in euros
PPP PPP-1. Price of cannabis products at retail level, 2005 Part (ii) Sources of information
PPP PPP-2. Price of heroin at retail level, 2005 Part (i) Minimum, maximum, mean and modal (typical) price in euros
PPP PPP-5. Potency of cannabis products at retail level, 2005 Part (i) Minimum, maximum, mean and modal (typical) potency recorded, measured as percentage of THC content
PPP PPP-5. Potency of cannabis products at retail level, 2005 Part (ii) Sources of information
PPP PPP-5. Potency of cannabis products at retail level, 2005 Part (iii) Sampling frame/type of study
GPS GPS-1. Lifetime prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population Part (i) Lifetime prevalence all adults (percentage)
GPS GPS-2. Lifetime prevalence of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population
GPS GPS-3. Last year prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population
GPS GPS-5. Last month prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population
GPS GPS-6. Last month prevalence of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population
GPS GPS-7. Last month prevalence and frequency of use of cannabis among all adults (aged 15 to 64 years old) and young adults (aged 15 to 34 years old) in nationwide surveys among the general population Part(i) Last month prevalence (percentage)
GPS GPS-7. Last month prevalence and frequency of use of cannabis among all adults (aged 15 to 64 years old) and young adults (aged 15 to 34 years old) in nationwide surveys among the general population Part(ii) Frequency of use among all users in last month (percentage)
GPS GPS-8. Lifetime prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population Part (i) Lifetime prevalence all adults (percentage): last survey available for each Member State
GPS GPS-9. Lifetime prevalence (percentage) of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population: last survey available for each Member State
GPS GPS-10. Last year prevalence (percentage) of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population: last survey available for each Member State
GPS GPS-11. Last year prevalence (percentage) of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population: last survey available for each Member State
GPS GPS-12. Last month prevalence (percentage) of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population: last survey available for each Member State
GPS GPS-13. Last month prevalence (percentage) of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population: last survey available for each Member State
GPS GPS-14. Lifetime prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population
GPS GPS-15. Last year prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population
GPS GPS-16. Last month prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population
GPS GPS-17. Lifetime prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population. Last survey available for each Member State
GPS GPS-18. Last year prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population. Last survey available for each Member State
GPS GPS-19. Last month prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population: last survey available for each Member State
GPS GPS-1. Last year prevalence of cannabis among all adults (aged 15 to 64 years old), young adults (aged 15 to 34 years old) and for the 15 to 24 years old age group, measured by national population surveys
GPS GPS-2. Continuation rates of cannabis (last year and last month use among lifetime users) in the general population, as measured by national surveys
GPS GPS-3. Last month prevalence of cannabis among the age group of 15 to 24 years, measured by national surveys
GPS GPS-4. Trends in last year prevalence of cannabis among young adults (aged 15 to 34), measured by national surveys
GPS GPS-10. Last year prevalence of cannabis by age group in United Kingdom, measured by national population surveys
GPS GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34) Part (i) Cannabis use – lifetime experience, last year and last month prevalence
GPS GPS-19. Comparison of drug use prevalence during last year by different user groups in the general population aged 15 to 34 – data for Spain, 1999
EYE EYE-1. Recent school surveys (2003-2005): Lifetime prevalence (percentage) of psychoactive substance use among students aged 15-16 years old
EYE EYE-2. Recent school surveys (2003-2005): lifetime percentage prevalence (LTP) of psychoactive substance use and last month prevalence (LMP) of cannabis among students aged 17 to 18 years
EYE EYE-3. School surveys: percentage lifetime prevalence of psychoactive substance use among students aged 15-16 years
EYE EYE-4. ESPAD 2003 school surveys: lifetime prevalence (percentages) of psychoactive substance use among students 15-16 years Part (i) Females
EYE EYE-4. ESPAD 2003 school surveys: lifetime prevalence (percentages) of psychoactive substance use among students 15-16 years Part (ii) Males
EYE EYE-5. ESPAD 2003 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15-16 years Part (i) All students
EYE EYE-5. ESPAD 2003 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15-16 years Part (ii) Males
EYE EYE-5. ESPAD 2003 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15-16 years Part (iii) Females
EYE EYE-6. All ESPAD school surveys: lifetime prevalence (percentages) of psychoactive substance use among students 15-16 years Part (i) Females
EYE EYE-6. All ESPAD school surveys: lifetime prevalence (percentages) of psychoactive substance use among students 15-16 years Part (ii) Males
EYE EYE-7. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15-16 years Part (i) All students
EYE EYE-7. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15-16 years Part (ii) Males
EYE EYE-7. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15-16 years Part (iii) Females
EYE EYE-1. Drug use among minors Part (ii) Changes between 1995 and 2003 in recalled use of cannabis at or before age 13 (percentage points) as reported by 15- to 16-year-old school students.
DUP DUP-3. Prevalence of drug use within prison among prisoners, 1995-2006
DUP DUP-1. Studies of lifetime prevalence of use of various drugs among prisoners in some EU Member States, 1999 to 2006
DLO DLO-3. Drug types involved in reports for drug law offences: percentage of all reports for drug law offences
DLO DLO-6. Cannabis-related offences: as percentage of all drug law offences, 1996 to 2005
DLO DLO-2. Cannabis-related offences in Europe, 2000-2005 Part (i) EU-15 Member States and Norway
DLO DLO-2. Cannabis-related offences in Europe, 2000-2005 Part (ii) new EU Member States and Turkey
DLO DLO-3. Percentage of drug law offences for use or possession for use related to cannabis in Europe, 2000-2005 Part (i) EU-15 Member States and Norway
DLO DLO-3. Percentage of drug law offences for use or possession for use related to cannabis in Europe, 2000-2005 Part (ii) New Member States and Turkey
TDI TDI-3. Distribution by primary drug used of new clients entering treatment, 1993 to 2005 Part (iii) Percent of new clients using cannabis
TDI TDI-4. Characteristics of new clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available Part (ii) Primary drug type used (percent of new clients using) and of those, the percent injecting it
TDI TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available Part (ii) Primary drug type used by clients (percent of all clients) and of those, the percent injecting it
TDI TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available Part (v) Primary drug type used by male clients (percent of all male clients)
TDI TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available Part (vi) Primary drug type used by female clients (percent of all female clients)
TDI TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005 Part (i) Distribution of new outpatient clients by age group for each primary drug
TDI TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005 Part (ii) Distribution of new outpatient clients by primary drug for each age group
TDI TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005 Part (iii) Distribution of all outpatient clients by age group for each primary drug
TDI TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005 Part (iv) Distribution of all outpatient clients by primary drug for each age group
TDI TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005 Part (v) Distribution of new inpatient clients by age group for each primary drug
TDI TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005 Part (vi) Distribution of new inpatient clients by primary drug for each age group
TDI TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005 Part (vii) Distribution of all inpatient clients by age group for each primary drug
TDI TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005 Part (viii) Distribution of all inpatient clients by primary drug for each age group
TDI TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005 Part (i) Distribution of new outpatient clients by age group for each primary drug
TDI TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005 Part (ii) Distribution of new outpatient clients by primary drug for each age group
TDI TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005 Part (iii) Distribution of all outpatient clients by age group for each primary drug
TDI TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005 Part (iv) Distribution of all outpatient clients by primary drug for each age group
TDI TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005 Part (v) Distribution of new inpatient clients by age group for each primary drug
TDI TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005 Part (vii) Distribution of all inpatient clients by age group for each primary drug
TDI TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005 Part (viii) Distribution of all inpatient clients by primary drug for each age group
TDI TDI-18. Frequency of use of primary drug among new and all outpatient and inpatient clients in 2005 Part (i) Percentage distribution amongst new outpatient clients
TDI TDI-18. Frequency of use of primary drug among new and all outpatient and inpatient clients in 2005 Part (ii) Percentage distribution amongst all outpatient clients
TDI TDI-18. Frequency of use of primary drug among new and all outpatient and inpatient clients in 2005 Part (iii) Percentage distribution amongst new inpatient clients
TDI TDI-18. Frequency of use of primary drug among new and all outpatient and inpatient clients in 2005 Part (iv) Percentage distribution amongst all inpatient clients
TDI TDI-19. New and all clients entering outpatient and inpatient treatment: distribution (percentage) by primary drug at treatment in 2005 for those countries supplying data Part (i) New clients entering outpatient treatment
TDI TDI-19. New and all clients entering outpatient and inpatient treatment: distribution (percentage) by primary drug at treatment in 2005 for those countries supplying data Part (ii) All clients entering outpatient treatment
TDI TDI-19. New and all clients entering outpatient and inpatient treatment: distribution (percentage) by primary drug at treatment in 2005 for those countries supplying data Part (iii) New clients entering inpatient treatment
TDI TDI-19. New and all clients entering outpatient and inpatient treatment: distribution (percentage) by primary drug at treatment in 2005 for those countries supplying data Part (iv) All clients entering inpatient treatment
TDI TDI-21. Gender ratio by primary drug - ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2005 for countries supplying data Part (i) Gender ratio (ratio of males to females) among new clients entering outpatient treatment
TDI TDI-21. Gender ratio by primary drug - ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2005 for countries supplying data Part (ii) Gender ratio (ratio of males to females) among all clients entering outpatient treatment
TDI TDI-21. Gender ratio by primary drug - ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2005 for countries supplying data Part (iii) Gender ratio (ratio of males to females) among new clients entering inpatient treatment
TDI TDI-21. Gender ratio by primary drug - ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2005 for countries supplying data Part (iv) Gender ratio (ratio of males to females) among all clients entering inpatient treatment
TDI TDI-22. Secondary drugs: number of citations by all clients in outpatient and inpatient centres in 2005: average for those EU countries supplying data Part (i) Outpatient centres
TDI TDI-22. Secondary drugs: number of citations by all clients in outpatient and inpatient centres in 2005: average for those EU countries supplying data Part (ii) Inpatient centres
TDI TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2005: the combination of opioids, cocaine, cannabis or other stimulants as primary drug type with a secondary drug Part (i) Most frequent combination of the primary drug with the stated types of secondary drug (percentages)
TDI TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2005: the combination of opioids, cocaine, cannabis or other stimulants as primary drug type with a secondary drug Part (ii) All clients with opioids as primary drug type: number of episodes reporting the stated drugs as secondary
TDI TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2005: the combination of opioids, cocaine, cannabis or other stimulants as primary drug type with a secondary drug Part (iii) All clients with cocaine as primary drug type: number of episodes reporting the stated drugs as secondary
TDI TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2005: the combination of opioids, cocaine, cannabis or other stimulants as primary drug type with a secondary drug Part (iv) All clients with cannabis as primary drug: number of episodes reporting the stated drug as secondary
TDI TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2005: the combination of opioids, cocaine, cannabis or other stimulants as primary drug type with a secondary drug Part (v) All clients with stimulants other than cocaine as primary drug type: number of episodes reporting the stated drugs as secondary
TDI TDI-24. All and new clients entering outpatient and inpatient treatment centres by main drug for which they ask for treatment in 2005 for those countries supplying data Part(i) All clients entering treatment by percentage of Outpatient and Inpatient treatment
TDI TDI-24. All and new clients entering outpatient and inpatient treatment centres by main drug for which they ask for treatment in 2005 for those countries supplying data Part(ii) New clients entering treatment by percentage of Outpatient and Inpatient treatment
TDI TDI-25. Age distribution (column percentage) by gender among all clients entering outpatient treatment with primary drug: opioids, cocaine, stimulants and cannabis in 2005 for countries supplying data
TDI TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2005 Part (iii) Percentage distribution amongst new clients with cannabis as primary drug
TDI TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2005 Part (iv) Percentage distribution amongst all clients with cannabis as primary drug
TDI TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2005 Part (iii) Percentage distribution amongst new clients with cannabis as primary drug
TDI TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2005 Part (iv) Percentage distribution amongst all clients with cannabis as primary drug
TDI TDI-118. Polydrug use with cocaine among all clients entering outpatient treatment, for countries supplying data for 2005 Part (ii) All clients with cocaine HCl as primary drug type: numbers of episodes reporting the stated drugs as secondary
TDI TDI-118. Polydrug use with cocaine among all clients entering outpatient treatment, for countries supplying data for 2005 Part (iii) All clients with crack as primary drug type: number of episodes reporting the stated drugs as secondary
TDI TDI-122. All outpatient clients under 15 entering treatment by primary drug in 2005 for those countries supplying data
TDI TDI-125. Primary drug of consumption among all drug clients under 15 entering drug treatment in 2005 in 6 EU countries + Turkey
TDI TDI-2. New and all clients entering treatment in 2005 by primary drug: heroin, cocaine, cannabis, other stimulants, other drugs (21 countries- 20 EU + TR - included for all clients and 22 countries - 21 EU + TK - for new clients)
GPS GPS-12. Last year prevalence of cannabis by age group in some Member States, measured by national population surveys – last survey available Part (ii) Last year prevalence in some new EU Member States

Page last updated: Tuesday, 20 March 2012